Drug Profile
Diabetic ulcer peptide therapy - Issar Pharma
Latest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Issar Pharma
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Diabetic foot ulcer
Most Recent Events
- 15 Feb 2022 Discontinued - Phase-II for Diabetic foot ulcer in India (Topical) (Issar Pharma pipeline, February 2022)
- 24 Oct 2016 Phase-II clinical trials in Diabetic foot ulcer in India (Topical) before October 2016 (Issar Pharmaceuticals pipeline, October 2016)
- 28 Apr 2016 Diabetic ulcer peptide therapy - Issar Pharma is available for licensing as of 28 Apr 2016. http://issar.co.in/